Somatostatin receptor expression in lung cancer.
Somatostatin receptor expression in lung cancer.
复制标题
肺癌中生长抑素受体的表达。
DOI：
10.1016/0959-8049(94)00351-5
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
Carney,DN
中科院分区：
文献类型：
--
作者：
O'Byrne,KJ;Halmos,G;Pinski,J;Groot,K;Szepeshazi,K;Schally,AV;Carney,DN
实验证据表明，生长抑素类似物可能在肺部肿瘤的治疗中发挥作用。我们评估了 9 种小细胞肺癌 (SCLC) 细胞系和 3 名非小细胞肺癌 (NSCLC) 患者、1 名非典型类癌患者和另一名支气管类癌患者的肿瘤样本的膜制剂中是否存在 RC-160（生长抑素的有效生长抑制性八肽类似物）的特异性结合位点。在九个 SCLC 系中的六个上注意到特异性结合。对细胞系 NCI H 69 的放射受体测定显示了 RC-160 的两个特异性结合位点的证据，一个具有高亲和力，另一个具有低亲和力。在所有五个肿瘤样本上也发现了结合位点。斯卡查德分析表明在每种情况下都存在具有高亲和力的一类受体。在结合测定之前对切除标本的组织学评估显示它们由肿瘤细胞和坏死组织、基质和/或炎症细胞组成。因此，RC-160的特异性结合可能是针对肿瘤细胞以外的组织。在获得肿瘤样本的 3 名患者中，在手术前使用[111In]喷曲肽进行放射性标记的生长抑素类似物闪烁扫描。在所有情况下，放射性标记都定位了疾病。这项研究证明了 SCLC 中存在 RC-160 特异性结合位点。此外，对NSCLC和肺内类癌的体外和体内特异性结合的检测表明，这些肿瘤含有表达生长抑素特异性结合位点的细胞。这些结果表明 RC-160 可能具有作为肺癌治疗剂的作用。
Experimental evidence suggests that somatostatin analogues may have a role to play in the management of lung tumours. We evaluated membrane preparations of nine small cell lung cancer (SCLC) cell lines and of tumour samples from 3 patients with non-small cell lung cancer (NSCLC), 1 patient with an atypical carcinoid and another with a bronchial carcinoid for the presence of specific binding sites for RC-160, a potent growth inhibitory octapeptide analogue of somatostatin. Specific binding was noted on six of nine SCLC lines. Radio-receptor assay on the cell line NCI H 69 showed evidence of two specific binding sites for RC-160, one with high affinity and the other with low affinity. Binding sites were also found on all five tumour samples. Scatchard analysis indicated the presence of a single class of receptors with high affinity in each case. Histological assessment of the resected specimens before binding assay showed them to be comprised of tumour cells and necrotic tissue, stroma and/or inflammatory cells. Therefore, the specific binding of RC-160 may be to tissues other than the tumour cells. In 3 patients, from whom the tumour samples were obtained, radiolabelled somatostatin analogue scintigraphy using [111In] pentetreotide was performed prior to surgery. In all cases, the radiolabel localised the disease. This study demonstrates the presence of specific binding sites for RC-160 in SCLC. Furthermore, the detection of specific bindingin vitroandin vivoin NSCLC and intrapulmonary carcinoids demonstrates that these tumours contain cells which express specific binding sites for somatostatin. These results suggest that RC-160 may have a role to play as a therapeutic agent in lung cancer.